Experience

BCL-2 inhibitors licensing agreement for Fochon Pharmaceuticals, Ltd.

Fochon Pharmaceuticals, Ltd.

Drafted and negotiated a complex license agreement for Fochon Pharmaceuticals, Ltd. relating to BCL-2 inhibitors with up to $400 million in potential development and commercial milestones.

Related Professionals

D. Brian Kacedon
Partner
Washington, DC
+1 202 408 4301
Email

Related Practices

Diligence, Licensing, and Opinions

Licensing, Pooling, and Other Transactions

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

InnoPharma Licensing, Inc.; Lupin Ltd.; and Metrics, Inc. v. Senju Pharmaceuticals Co.

Bausch Health Companies

Multiple settlement and license agreements for AbbVie, Inc.

AbbVie, Inc.

Lipid nanoparticle licensing and collaboration agreements for Genevant Sciences

Genevant Sciences

International film distribution and licensing agreement

Wyeth v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.

Wyeth

Drafted and negotiated settlement agreements, co-existence agreements, and licensing contracts across Latin American jurisdictions

Mylan Pharmaceuticals Inc. v. Senju Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd.; Bausch & Lomb Incorporated

Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.

Otsuka Pharmaceutical Co. Ltd.

Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.

Otsuka Pharmaceutical Co.

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.